Marinus Pharmaceuticals Statistics

Share Statistics

Marinus Pharmaceuticals has 55.22M shares outstanding. The number of shares has increased by 0.52% in one year.

Shares Outstanding Shares Outstanding n/a Close	55.22M
Shares Change (YoY) Shares Change (YoY) n/a Close	0.52%
Shares Change (QoQ) Shares Change (QoQ) n/a Close	0.06%
Owned by Institutions (%) Owned by Institutions (%) n/a Close	72.28%
Shares Floating Shares Floating n/a Close	37.39M
Failed to Deliver (FTD) Shares Failed to Deliver (FTD) Shares n/a Close	61,426
FTD / Avg. Volume FTD / Avg. Volume n/a Close	3.39%

Short Selling Information

The latest short interest is 2.18M, so 3.95% of the outstanding shares have been sold short.

Short Interest Short Interest n/a Close	2.18M
Short % of Shares Out Short % of Shares Out n/a Close	3.95%
Short % of Float Short % of Float n/a Close	3.96%
Short Ratio (days to cover) Short Ratio (days to cover) n/a Close	1.44

Valuation Ratios

The PE ratio is -1.03 and the forward PE ratio is -2.62. Marinus Pharmaceuticals's PEG ratio is 0.

PE Ratio PE Ratio n/a Close	-1.03
Forward PE Forward PE n/a Close	-2.62
PS Ratio PS Ratio n/a Close	4.72
Forward PS Forward PS n/a Close	0.3
PB Ratio PB Ratio n/a Close	8.72
P/FCF Ratio P/FCF Ratio n/a Close	-1.24
PEG Ratio PEG Ratio n/a Close	0

Financial Ratio History

Enterprise Valuation

Marinus Pharmaceuticals has an Enterprise Value (EV) of 135.98M.

EV / Sales EV / Sales n/a Close	4.39
EV / EBITDA EV / EBITDA n/a Close	-1.08
EV / EBIT EV / EBIT n/a Close	-1.15
EV / FCF EV / FCF n/a Close	-1.15

Financial Position

The company has a current ratio of 4.07, with a Debt / Equity ratio of 6.58.

Current Ratio Current Ratio n/a Close	4.07
Quick Ratio Quick Ratio n/a Close	4.01
Debt / Equity Debt / Equity n/a Close	6.58
Debt / EBITDA Debt / EBITDA n/a Close	-0.88
Debt / FCF Debt / FCF n/a Close	-0.93
Interest Coverage Interest Coverage n/a Close	-7.78

Financial Efficiency

Return on Equity is -843.45% and Return on Invested Capital is -89.82%.

Return on Equity Return on Equity n/a Close	-843.45%
Return on Assets Return on Assets n/a Close	-82.74%
Return on Invested Capital Return on Invested Capital n/a Close	-89.82%
Revenue Per Employee Revenue Per Employee n/a Close	$187,812.12
Profits Per Employee Profits Per Employee n/a Close	$-857,000
Employee Count Employee Count n/a Close	165
Asset Turnover Asset Turnover n/a Close	0.18
Inventory Turnover Inventory Turnover n/a Close	0.8

Taxes

Income Tax Income Tax n/a Close	-1.54M
Effective Tax Rate Effective Tax Rate n/a Close	1.08%

Stock Price Statistics

The stock price has increased by -61.81% in the last 52 weeks. The beta is 1.26, so Marinus Pharmaceuticals's price volatility has been higher than the market average.

Beta Beta n/a Close	1.26
52-Week Price Change 52-Week Price Change n/a Close	-61.81%
50-Day Moving Average 50-Day Moving Average n/a Close	0.43
200-Day Moving Average 200-Day Moving Average n/a Close	1.06
Relative Strength Index (RSI) Relative Strength Index (RSI) n/a Close	70.4
Average Volume (20 Days) Average Volume (20 Days) n/a Close	1,810,773

Income Statement

In the last 12 months, Marinus Pharmaceuticals had revenue of 30.99M and earned -141.41M in profits. Earnings per share was -2.63.

Revenue Revenue n/a Close	30.99M
Gross Profit Gross Profit n/a Close	29.05M
Operating Income Operating Income n/a Close	-131.49M
Net Income Net Income n/a Close	-141.41M
EBITDA EBITDA n/a Close	-125.5M
EBIT EBIT n/a Close	-126.05M
Earnings Per Share (EPS) Earnings Per Share (EPS) n/a Close	-2.63

Full Income Statement

Balance Sheet

The company has 120.57M in cash and 110.36M in debt, giving a net cash position of 10.21M.

Cash & Cash Equivalents Cash & Cash Equivalents n/a Close	120.57M
Total Debt Total Debt n/a Close	110.36M
Net Cash Net Cash n/a Close	10.21M
Retained Earnings Retained Earnings n/a Close	-571.93M
Total Assets Total Assets n/a Close	63.62M
Working Capital Working Capital n/a Close	22.9M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -118M and capital expenditures -119K, giving a free cash flow of -118.12M.

Operating Cash Flow Operating Cash Flow n/a Close	-118M
Capital Expenditures Capital Expenditures n/a Close	-119K
Free Cash Flow Free Cash Flow n/a Close	-118.12M
FCF Per Share FCF Per Share n/a Close	-2.2

Full Cash Flow Statement

Margins

Gross margin is 93.76%, with operating and profit margins of -424.3% and -456.31%.

Gross Margin Gross Margin n/a Close	93.76%
Operating Margin Operating Margin n/a Close	-424.3%
Pretax Margin Pretax Margin n/a Close	-461.27%
Profit Margin Profit Margin n/a Close	-456.31%
EBITDA Margin EBITDA Margin n/a Close	-404.97%
EBIT Margin EBIT Margin n/a Close	-424.3%
FCF Margin FCF Margin n/a Close	-381.17%

Dividends & Yields

MRNS does not appear to pay any dividends at this time.

Dividend Per Share Dividend Per Share n/a Close	n/a
Dividend Yield Dividend Yield n/a Close	n/a
Dividend Growth (YoY) Dividend Growth (YoY) n/a Close	n/a
Payout Ratio Payout Ratio n/a Close	n/a
Earnings Yield Earnings Yield n/a Close	-96.73%
FCF Yield FCF Yield n/a Close	-80.8%

Dividend Details

Analyst Forecast

The average price target for MRNS is $3, which is 445.5% higher than the current price. The consensus rating is "Hold".

Price Target Price Target n/a Close	$3
Price Target Difference Price Target Difference n/a Close	445.5%
Analyst Consensus Analyst Consensus n/a Close	Hold
Analyst Count Analyst Count n/a Close	11

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value Lynch Fair Value n/a Close	n/a
Lynch Upside Lynch Upside n/a Close	n/a
Graham Number Graham Number n/a Close	n/a
Graham Upside Graham Upside n/a Close	n/a

Stock Splits

The last stock split was on Sep 23, 2020. It was a backward split with a ratio of 1:4.

Last Split Date Last Split Date n/a Close	Sep 23, 2020
Split Type Split Type n/a Close	backward
Split Ratio Split Ratio n/a Close	1:4

Scores

Altman Z-Score Altman Z-Score n/a Close	-20.13
Piotroski F-Score Piotroski F-Score n/a Close	3

Marinus Pharmaceuticals I... (MRNS)